Apple allergy is common in patients allergic to birch pollen, and this is defined as 'birch-apple syndrome'. Allergens responsible for cross-reactivity belong to the pathogenesis-related-10 family, and high homology in the amino acid sequences of the major allergens Bet v 1 from birch and Mal d 1 from apple has been demonstrated. Here we review the literature on the treatment of birch-apple syndrome by allergen immunotherapy. The only allergen immunotherapy method available thus far is based on the administration of birch-pollen extracts, through the subcutaneous or sublingual route, to induce tolerance to Bet v1 and to the homologous allergen Mal d 1. However, the studies performed thus far show modest efficacy, and thus other methods of immunotherapy should be investigated.
Allergen immunotherapy for birch-apple syndrome: what do we know? / I. Cristoforo, R. Erminia, M. Marina, R. Marina, E. Pastorello. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - 9:15(2017 Nov), pp. 1271-1278.
Titolo: | Allergen immunotherapy for birch-apple syndrome: what do we know? | |
Autori: | ||
Parole Chiave: | allergen immunotherapy; apple; birch pollen; birch-apple syndrome; cross-reactivity; pathogenesis-related proteins | |
Settore Scientifico Disciplinare: | Settore MED/09 - Medicina Interna | |
Data di pubblicazione: | nov-2017 | |
Rivista: | ||
Tipologia: | Article (author) | |
Digital Object Identifier (DOI): | http://dx.doi.org/10.2217/imt-2017-0040 | |
Appare nelle tipologie: | 01 - Articolo su periodico |
File in questo prodotto:
File | Descrizione | Tipologia | Licenza | |
---|---|---|---|---|
pastorello-Immunotherapy.pdf | Publisher's version/PDF | Administrator Richiedi una copia |